Christopher G Wood

List of Publications by Year
in descending order

230 papers	13,097 citations	20759 60 h-index	28224 105 g-index
243 all docs	243 docs citations	243 times ranked	10461 citing authors

#	Article	IF	Citations
1	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009, 115, 1224-1233.	2.0	943
2	Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience. Journal of Clinical Oncology, 2005, 23, 2763-2771.	0.8	652
3	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 rgBT /Overlock 10	6.3	529
4	Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. Journal of Clinical Oncology, 2004, 22, 3316-3322.	0.8	353
5	Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. European Urology, 2012, 62, 100-114.	0.9	349
6	An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet, The, 2008, 372, 145-154.	6.3	312
7	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. European Urology, 2016, 69, 866-874.	0.9	272
8	Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. European Journal of Endocrinology, 2013, 169, 891-899.	1.9	235
9	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for highâ€risk upper tract transitional cell carcinoma. Cancer, 2010, 116, 3127-3134.	2.0	208
10	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. European Urology, 2015, 68, 980-992.	0.9	206
11	Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 4076-4081.	0.8	183
12	Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer, 2010, 116, 3378-3388.	2.0	183
13	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2010, 184, 453-458.	0.2	182
14	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
15	The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus. European Urology, 2011, 59, 912-918.	0.9	167
16	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1017-1029.	1.6	159
17	Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. Journal of Urology, 2008, 180, 94-98.	0.2	157
18	Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nature Communications, 2017, 8, 783.	5.8	157

#	Article	IF	Citations
19	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. European Urology, 2010, 57, 1072-1079.	0.9	155
20	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European Urology, 2010, 57, 575-581.	0.9	154
21	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer, 2014, 120, 1794-1799.	2.0	154
22	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. Journal of Urology, 2013, 189, 1662-1669.	0.2	152
23	Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma. European Urology, 2014, 66, 874-880.	0.9	131
24	Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and Spectrum of Disease. Radiographics, 2009, 29, 741-754.	1.4	123
25	Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes. Clinical Cancer Research, 2014, 20, 4129-4140.	3.2	117
26	Renal Cell Carcinoma With Nodal Metastases in the Absence of Distant Metastatic Disease (Clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2006, 175, 864-869.	0.2	116
27	Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. BJU International, 2006, 98, 1176-1180.	1.3	116
28	Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Urology, 2011, 185, 439-444.	0.2	113
29	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European Urology, 2016, 70, 348-357.	0.9	111
30	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	5.8	106
31	Spontaneous Regression of Pulmonary Metastases From Renal Cell Carcinoma After Radio Frequency Ablation of Primary Tumor: In Situ Tumor Vaccine?. Journal of Urology, 2003, 170, 178-179.	0.2	104
32	Discovery and Characterization of Endometrial Epithelial Messenger Ribonucleic Acids Using the Ovine Uterine Gland Knockout Model1. Endocrinology, 1999, 140, 4070-4080.	1.4	103
33	Chylous Ascites After Post-Chemotherapy Retroperitoneal Lymph Node Dissection: Review of the M. D. Anderson Experience. Journal of Urology, 2006, 176, 1463-1467.	0.2	101
34	Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. European Urology, 2014, 66, 584-592.	0.9	100
35	Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2011, 59, 10-15.	0.9	98
36	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. European Urology, 2013, 63, 1082-1090.	0.9	98

#	Article	IF	Citations
37	Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer, 2008, 112, 1480-1488.	2.0	95
38	Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. Oncogene, 1997, 14, 1697-1704.	2.6	94
39	Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma. Journal of Urology, 2009, 181, 2044-2051.	0.2	94
40	Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. European Urology, 2010, 58, 819-828.	0.9	89
41	Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. European Urology, 2011, 60, 964-971.	0.9	89
42	Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. European Urology, 2013, 63, 1122-1127.	0.9	88
43	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. Journal of Clinical Oncology, 2019, 37, 2062-2071.	0.8	80
44	Programmed cell death ligand 1 and tumorâ€infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer, 2017, 123, 4823-4831.	2.0	79
45	Genomic Heterogeneity of Translocation Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 4673-4684.	3.2	77
46	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. Journal of Urology, 2014, 192, 1050-1056.	0.2	76
47	Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Therapy, 1999, 6, 313-321.	2.2	75
48	Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Annals of Surgery, 2018, 268, 172-178.	2.1	75
49	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell, 2020, 37, 720-734.e13.	7.7	74
50	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 716-723.	0.8	73
51	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2019, 2, 141-149.	2.6	73
52	Upper urinary tract urothelial carcinoma with locoâ€regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU International, 2011, 108, 1286-1291.	1.3	71
53	Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. Journal of Urology, 2018, 199, 393-400.	0.2	70
54	Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib. European Urology, 2011, 60, 1273-1279.	0.9	69

#	Article	IF	Citations
55	Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. Clinical Cancer Research, 2007, 13, 697s-702s.	3.2	68
56	Renal cell carcinoma clinically involving adjacent organs. Cancer, 2007, 109, 2025-2030.	2.0	68
57	Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison With Nephrectomy Assessment. Journal of Urology, 2010, 184, 1877-1881.	0.2	67
58	Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. European Urology, 2013, 63, 947-952.	0.9	67
59	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clinical Cancer Research, 2017, 23, 6686-6696.	3.2	66
60	Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU International, 2016, 117, 775-782.	1.3	65
61	Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. International Journal of Urology, 2012, 19, 1060-1066.	0.5	64
62	Treatment of patients with metastatic renal cell cancer. Cancer, 2006, 107, 2375-2383.	2.0	63
63	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma With Nonclear Cell Histology. Journal of Urology, 2007, 178, 1896-1900.	0.2	62
64	Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease. Cancer, 2009, 115, 2355-2360.	2.0	62
65	Cytoreductive Nephrectomy in the Elderly Patient: The M. D. Anderson Cancer Center Experience. Journal of Urology, 2007, 177, 855-861.	0.2	61
66	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urologyâ€“Young Academic Urologists and theÂUpper Tract Urothelial Carcinoma Collaboration. BJU International, 2018, 121, 252-259.	1.3	61
67	A renal mass in the setting of a nonrenal malignancy. Cancer, 2004, 101, 2195-2201.	2.0	59
68	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2017, 198, 1253-1262.	0.2	58
69	Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma. European Urology, 2011, 59, 619-628.	0.9	57
70	The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Therapeutic Advances in Urology, 2016, 8, 130-141.	0.9	57
71	Redefining pT3 renal cell carcinoma in the modern era. Cancer, 2007, 109, 2439-2444.	2.0	55
72	Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU International, 2012, 110, 1742-1746.	1.3	55

#	Article	IF	Citations
73	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. Urology, 2013, 81, 972-978.	0.5	55
74	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. Journal of Urology, 2017, 198, 530-537.	0.2	55
75	Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU International, 2009, 104, 456-460.	1.3	53
76	Can a Durable Disease-Free Survival be Achieved With Surgical Resection in Patients With Pathological Node Positive Renal Cell Carcinoma?. Journal of Urology, 2011, 186, 1236-1241.	0.2	53
77	Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center experience. Urology, 2006, 68, 528-532.	0.5	51
78	The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urologic Clinics of North America, 2003, 30, 581-588.	0.8	50
79	Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology, 2015, 194, 316-322.	0.2	49
80	DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clinical Cancer Research, 2016, 22, 6236-6246.	3.2	47
81	Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. Journal of Urology, 2017, 198, 281-288.	0.2	47
82	Surgical Management of Renal Cell Carcinoma. Seminars in Interventional Radiology, 2014, 31, 027-032.	0.3	46
83	Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World Journal of Urology, 2014, 32, 631-642.	1.2	45
84	Adjuvant Therapy for Renal Cell Carcinoma. Seminars in Oncology, 2006, 33, 576-582.	0.8	44
85	Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nature Reviews Urology, 2009, 6, 375-383.	1.9	44
86	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU International, 2011, 108, E304-E309.	1.3	44
87	Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 166.e21-166.e29.	0.8	44
88	Mucinous tubular and spindle cell carcinoma (<scp>MTSCC</scp>) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU International, 2015, 116, 85-92.	1.3	44
89	Vitespen: a preclinical and clinical review. Future Oncology, 2009, 5, 763-774.	1.1	43
90	Autotaxinâ€“Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 6461-6472.	3.2	41

#	Article	IF	Citations
91	Biomarkers of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 243-251.	0.8	40
92	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer, 2016, 122, 1836-1843.	2.0	39
93	Risk factors for recurrence after surgery in nonâ€metastatic <scp>RCC</scp> with thrombus: a contemporary multicentre analysis. BJU International, 2016, 117, E87-94.	1.3	39
94	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	0.9	39
95	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2015, 193, 1486-1493.	0.2	38
96	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Research, 2015, 75, 4131-4142.	0.4	38
97	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 121-130.	1.2	37
98	Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e1-388.e9.	0.8	36
99	Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World Journal of Urology, 2018, 36, 1093-1101.	1.2	36
100	Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 427.e17-427.e23.	0.8	35
101	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2017, 197, 580-589.	0.2	35
102	Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Modern Pathology, 2019, 32, 1698-1707.	2.9	35
103	Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. American Journal of Pathology, 2018, 188, 2487-2496.	1.9	34
104	Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer, 2020, 126, 3950-3960.	2.0	34
105	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	1.2	33
106	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. Journal of Endourology, 2017, 31, 946-953.	1.1	33
107	The Role of Lymph Node Dissection in Renal Cell Carcinoma: The Pendulum Swings Back. Cancer Journal (Sudbury, Mass), 2008, 14, 308-314.	1.0	32
108	Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. Urology, 2009, 73, 337-341.	0.5	32

#	Article	IF	Citations
109	Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. Urology, 2011, 77, 861-866.	0.5	31
110	Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer, 2018, 124, 4023-4031.	2.0	30
111	Positive vascular wall margins have minimal impact on cancer outcomes in patients with nonâ€metastatic renal cell carcinoma (<scp>RCC</scp>) with tumour thrombus. BJU International, 2014, 114, 667-673.	1.3	29
112	Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 561-568.	0.8	28
113	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 379-385.	0.9	27
114	Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. Journal of Urology, 2017, 198, 810-816.	0.2	26
115	Cytoreductive Nephrectomy in the Era of Targeted Molecular Agents: Is It Time to Consider Presurgical Systemic Therapy?. European Urology, 2008, 54, 489-492.	0.9	25
116	International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma. European Urology, 2011, 60, 673-683.	0.9	25
117	Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. Journal of Urology, 2013, 190, 452-457.	0.2	25
118	Prognostic significance of promoter CpG island methylation of obesityâ€related genes in patients with nonmetastatic renal cell carcinoma. Cancer, 2017, 123, 3617-3627.	2.0	25
119	Type III Transforming Growth Factor-Î² (TGF-Î²) Receptor Mediates Apoptosis in Renal Cell Carcinoma Independent of the Canonical TGF-Î² Signaling Pathway. Clinical Cancer Research, 2008, 14, 5722-5730.	3.2	24
120	Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. Urologic Clinics of North America, 2012, 39, 211-231.	0.8	24
121	The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. Journal of Urology, 2016, 196, 678-684.	0.2	24
122	Geneâ€environment interaction of genomeâ€wide association studyâ€identified susceptibility loci and meatâ€cooking mutagens in the etiology of renal cell carcinoma. Cancer, 2016, 122, 108-115.	2.0	24
123	Cytoreductive Nephrectomy for T4NxM1 Renal Cell Carcinoma: The M.D. Anderson Cancer Center Experience. Urology, 2007, 69, 835-838.	0.5	23
124	Surgical considerations for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 528-537.	0.8	23
125	Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psycho-Oncology, 2015, 24, 1477-1484.	1.0	23
126	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Modern Pathology, 2015, 28, 1225-1235.	2.9	23

#	Article	IF	Citations
127	Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers, 2020, 12, 3755.	1.7	23
128	The Role of Surgery in Advanced Renal Cell Carcinoma: Cytoreductive Nephrectomy and Metastasectomy. Hematology/Oncology Clinics of North America, 2011, 25, 753-764.	0.9	22
129	Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Caseâ€"Control Study. Clinical Cancer Research, 2016, 22, 2074-2082.	3.2	22
130	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 113-120.	1.2	22
131	Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psycho-Oncology, 2017, 26, 1361-1368.	1.0	22
132	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International, 2022, 129, 610-620.	1.3	22
133	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nature Communications, 2021, 12, 6375.	5.8	22
134	Neuroendocrine Tumors of the Kidney: A Single Institution Experience. Clinical Genitourinary Cancer, 2014, 12, 422-427.	0.9	21
135	Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU International, 2020, 126, 745-753.	1.3	20
136	The role of lymphadenectomy in renal cell carcinoma. Current Opinion in Urology, 2009, 19, 465-472.	0.9	19
137	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology, 2018, 115, 119-124.	0.5	19
138	Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology, 2018, 116, 114-119.	0.5	19
139	Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2019, 18, 1937-1946.	1.9	19
140	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. Urology, 2014, 84, 1134-1140.	0.5	18
141	Variability of interâ€observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (<scp>RCC</scp>): independent analysis from a phase <scp>II</scp> trial. BJU International, 2016, 117, 629-635.	1.3	18
142	Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis, 2018, 39, 752-757.	1.3	18
143	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. European Urology Focus, 2020, 6, 104-111.	1.6	18
144	Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers, 2021, 13, 4006.	1.7	18

#	Article	IF	Citations
145	Cytoreductive nephrectomy in metastatic renal cell carcinoma. Current Opinion in Urology, 2008, 18, 474-480.	0.9	17
146	Adjuvant and neoadjuvant therapy for renal cell carcinoma: A survey of the Society of Urologic Oncology. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1316-1320.	0.8	17
147	Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clinical Genitourinary Cancer, 2017, 15, 363-370.	0.9	17
148	Adjuvant therapy for advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 663-671.	1.1	17
149	Preâ€surgical targeted molecular therapy in renal cell carcinoma. BJU International, 2009, 103, 150-153.	1.3	16
150	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology, 2016, 94, 314.e1-314.e7.	0.5	16
151	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e15-495.e22.	0.8	15
152	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers, 2021, 13, 2170.	1.7	15
153	The RENAL Nephrometry Nomogram: Statistically Significant, But Is It Clinically Relevant?. European Urology, 2011, 60, 249-251.	0.9	14
154	Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. European Urology, 2016, 69, 352-360.	0.9	14
155	Conditional survival of patients with small renal masses undergoing active surveillance. BJU International, 2019, 123, 447-455.	1.3	14
156	Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. European Urology Oncology, 2020, 3, 687-694.	2.6	14
157	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clinical Genitourinary Cancer, 2021, 19, e401-e408.	0.9	14
158	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers, 2021, 13, 6022.	1.7	14
159	Renal Cell Carcinoma: What the Surgeon and Treating Physician Need to Know. American Journal of Roentgenology, 2011, 196, 1255-1262.	1.0	13
160	Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 237.e19-237.e26.	0.8	13
161	BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia, 2018, 20, 32-43.	2.3	13
162	Partial Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma. Journal of Urology, 2014, 192, 36-42.	0.2	12

#	Article	IF	Citations
163	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 1073-1080.	1.2	12
164	Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. European Urology Focus, 2021, 7, 397-403.	1.6	12
165	Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncology, 2009, 5, 859-869.	1.1	11
166	The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology, 2017, 108, 114-121.	0.5	11
167	Salvage topical therapy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 2027-2034.	1.2	11
168	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight, 2020, 5, .	2.3	11
169	Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 614-621.	0.7	10
170	Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial. Journal of Urology, 2017, 197, 559-565.	0.2	10
171	Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 329-343.	0.8	10
172	Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. Journal of Surgical Oncology, 2006, 94, 264-265.	0.8	9
173	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Current Oncology Reports, 2008, 10, 253-258.	1.8	9
174	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World Journal of Urology, 2015, 33, 1965-1972.	1.2	9
175	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2019, 37, 2419-2427.	1.2	9
176	Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1239-1246.	1.8	9
177	A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Laboratory Investigation, 2022, 102, 554-559.	1.7	9
178	A vaccine for renal cancer. Lancet, The, 2008, 372, 1460-1461.	6.3	8
179	Realâ€Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angewandte Chemie - International Edition, 2019, 58, 4179-4183.	7.2	8
180	Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers, 2022, 14, 1127.	1.7	8

#	Article	IF	Citations
181	Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2017, 1, 115-121.	0.2	7
182	Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments. Cancer, 2008, 112, 955-961.	2.0	6
183	The Role of Lymph Node Dissection in Renal Cell Carcinoma. Urologic Clinics of North America, 2011, 38, 419-428.	0.8	6
184	The role of lymph node dissection in renal cell carcinoma. International Journal of Clinical Oncology, 2011, 16, 186-94.	1.0	6
185	Refining the Use of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Seminars in Oncology, 2013, 40, 429-435.	0.8	6
186	Reporting Geographic and Temporal Trends in Renal Cell Carcinoma: Why Is This Important?. European Urology, 2015, 67, 531-532.	0.9	6
187	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 496-505.	0.8	6
188	Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Translational Andrology and Urology, 2021, 10, 2233-2245.	0.6	6
189	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2013, 190, 386-388.	0.2	5
190	Treating the Two Extremes in Renal Cell Carcinoma: Management of Small Renal Masses and Cytoreductive Nephrectomy in Metastatic Disease. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e214-e221.	1.8	5
191	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Journal of Urology, 2017, 198, 1269-1277.	0.2	5
192	Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliative and Supportive Care, 2018, 16, 146-154.	0.6	5
193	Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Annals of Translational Medicine, 2020, 8, 1037-1037.	0.7	5
194	Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer, 2020, 126, 4878-4885.	2.0	5
195	Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. International Journal of Molecular Sciences, 2021, 22, 2849.	1.8	5
196	Adjuvant approaches to renal cell carcinoma. Clinical Advances in Hematology and Oncology, 2008, 6, 19-21.	0.3	5
197	Update on staging controversies for locally advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2007, 7, 909-914.	1.1	4
198	Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 676-681.	0.8	4

#	Article	IF	Citations
199	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	1.2	4
200	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	0.8	4
201	PERCUTANEOUS PRIMARY TUMOR BIOPSY IS UNRELIABLE TO PREDICT HIGH RISK PATHOLOGIC FEATURES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 501-501.	0.2	3
202	Feasibility of Contrastâ€Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy. Journal of Ultrasound in Medicine, 2017, 36, 1547-1553.	0.8	3
203	Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 790.e17-790.e23.	0.8	3
204	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 837.e9-837.e17.	0.8	3
205	Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treatment and Research Communications, 2021, 27, 100349.	0.7	3
206	Cytoreductive surgery in the era of targeted molecular therapy. Translational Andrology and Urology, 2015, 4, 301-9.	0.6	3
207	Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cancer?. Cancer, 2008, 113, 1282-1283.	2.0	2
208	The Effects of Temporary Ischemia in Partial Nephrectomy on Renal Functional Outcomes: How Can Effects Best Be Estimated, and Can They Be Mitigated?. European Urology, 2012, 62, 136-138.	0.9	2
209	Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. European Urology, 2012, 62, 182-183.	0.9	2
210	Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1436-1442.	1.1	2
211	Longâ€term renal functional outcomes following ureteroureterostomy performed during multiâ€organ resection for nonâ€urothelial cancers. BJUI Compass, 2021, 2, 348-354.	0.7	2
212	Re: Prognostic or Predictive Plasma Cytokines and Angiogenic Factors for Patients Treated with Pazopanib for Metastatic Renal-cell Cancer: A Retrospective Analysis of Phase 2 and Phase 3 Trials. European Urology, 2013, 63, 769.	0.9	1
213	Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	1
214	Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. American Journal of Roentgenology, 2021, 217, 1-7.	1.0	1
215	Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Groupâ€American College of Radiology Imaging Network (ECOGâ€ACRIN) E2805. BJU International, 2022, 129, 718-722.	1.3	1
216	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian Journal of Urology, 2021, 37, 13-19.	0.2	1

#	Article	IF	Citations
217	Predictive capacity of a miRNA panel in identifying teratoma in postâ€chemotherapy consolidation surgeries. BJUI Compass, 2023, 4, 81-87.	0.7	1
218	Local recurrence after primary therapy for clinically localized prostate cancer: Is radiation or surgery â€œBetterâ€•in the salvage setting?. Journal of Surgical Oncology, 2008, 97, 376-376.	0.8	0
219	Renal Tumors. , 2012, , 287-309.		0
220	Locally Advanced Renal Cell Carcinoma. , 2013, , 197-218.		0
221	Surgical Treatment for Renal Cell Carcinoma. , 2017, , 221-235.		0
222	Editorial Comment. Journal of Urology, 2018, 199, 52-52.	0.2	0
223	Radical Nephrectomy is the Treatment of Choice for Complex, Localized Renal Tumors. Kidney Cancer, 2018, 2, 5-9.	0.2	0
224	Realâ€Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angewandte Chemie, 2019, 131, 4223-4227.	1.6	0
225	EDITORIAL COMMENT. Urology, 2020, 136, 175.	0.5	0
226	Metabolic evaluation of sporadic papillary kidney cancer.. Journal of Clinical Oncology, 2012, 30, 377-377.	0.8	0
227	Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. , 2013, , 155-177.		0
228	Cytoreductive Nephrectomy. , 2015, , 157-171.		0
229	Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU International, 2021, , .	1.3	0
230	Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients.. American Journal of Cancer Research, 2022, 12, 852-860.	1.4	0